Adverse effects associated with favipiravir in patients with COVID-19 pneumonia
a retrospective study
Keywords:
Favipiravir [supplementary concept], COVID-19, PneumoniaAbstract
BACKGROUND: Favipiravir is generally used in treating coronavirus disease 2019 (COVID-19) pneumonia in Turkey. OBJECTIVE: To determine the side effects of favipiravir and whether it is a good treatment option. DESIGN AND SETTING: Retrospective study conducted in Atatürk Chest Diseases and Chest Surgery Training and Research Hospital, Ankara, Turkey. METHODS: 357 patients who completed favipiravir treatment at the recommended dose were included 37 patients with drug side effects and 320 patients without drug side effects were examined in two groups. RESULTS: Side effects were observed in 37 (10.36%) out of 357 patients using favipiravir. The most common side effect was liver dysfunction, in 26 (7.28%) of the patients. The following other side effects were also observed: diarrhea (1.4%), nausea (0.84%), abdominal pain (0.28%) and thrombocytopenia (0.28%). One patient (0.28%) presented both increased transaminases and nausea. CONCLUSION: In this study, it was determined that favipiravir may constitute an alternative for treating COVID-19 pneumonia given that its side effects are generally well tolerated and not serious.
Downloads
References
Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687-90. PMID: 32208840; https://doi.org/10.1080/22221751.2020.1741327.
He F, Deng Y, Li W. Coronavirus disease 2019: What we know? J Med Virol. 2020;92(7):719-25. PMID: 32170865; https://doi.org/10.1002/jmv.25766.
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71. PMID: 32020029; https://doi.org/10.1038/s41422-020-0282-0.
De Clercq E. New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chem Asian J. 2019;14(22):3962-8. PMID: 31389664; https://doi.org/10.1002/asia.201900841.
Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020;76(4):370-6. PMID: 32895599; https://doi.org/10.1016/j.mjafi.2020.08.004.
Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clin Infect Dis. 2019;68(6):895-902. PMID: 30834445; https://doi.org/10.1093/cid/ciy874.
Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9(6):399-406. PMID: 14660806.
Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-66. PMID: 32034323; https://doi.org/10.1038/s41584-020-0372-x.
Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. PMID: 32194981; https://doi.org/10.1038/s41421-020-0156-0.
Mentré F, Taburet AM, Guedj J, et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2015;15(2):150-1. PMID: 25435054; https://doi.org/10.1016/S1473-3099(14)71047-3.
Toyama Chemicals. Summary of Product Characteristics of Avigan. Report on the Deliberation Results. Available from: https://www.pmda.go.jp/files/000210319.pdf Accessed in 2021 (Aug 25).
Madelain V, Nguyen TH, Olivo A, et al. Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trial. Clin Pharmacokinet. 2016;55(8):907-23. PMID: 26798032; https://doi.org/10.1007/s40262-015-0364-1.
Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512. PMID: 32097670; https://doi.org/10.1016/j.pharmthera.2020.107512.
Du YX, Chen XP. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther. 2020;108(2):242-7. PMID: 32246834; https://doi.org/10.1002/cpt.1844.
Türkiye Cumhuriyeti Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü Covid-19 Yönergesi 14.04.2020. Available from: https://covid19rehberi.com/covid-19-eriskin-hasta-tedavisi-14-04-2020/html Accessed in 2021 (Aug 25).
Chen C, Huang J, Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial [Internet]. medRxiv [Preprint]. 2020. https://doi.org/10.1101/2020.03.17.20037432.
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-63. PMID: 28769016; https://doi.org/10.2183/pjab.93.027.
Liverpool Drug Interactions Group. Interactions with experimental covid-19 therapies, 20.03.2020. Available from: https://gtr.ukri.org/projects?ref=MR%2FV020498%2F1 Accessed in 2021 (Aug 25).
Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. PMID: 16115318; https://doi.org/10.1186/1743-422X-2-69.
